Navigation Links
Perrigo Company Announces Dividend Increase

ALLEGAN, Mich., Oct. 29 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.0625 per share, payable on December 15, 2009 to shareholders of record on November 27, 2009. The new quarterly dividend of $0.0625 per share represents a twelve percent increase over $0.055 per share paid in the last four quarters.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (

SOURCE Perrigo Company

SOURCE Perrigo Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
2. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
3. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
4. Perrigo Confirms Filing for Generic Version of Mens Rogaine(R) Foam
5. Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009
6. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
7. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
8. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
9. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes
10. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity
11. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 /PRNewswire/ ... announced the addition of the  "Global ...  report to their offering.  ... the addition of the  "Global Drug ...  report to their offering.  --> ...
(Date:11/24/2015)...  Array BioPharma Inc. (Nasdaq: ARRY ) ... Ron Squarer , will present at the Piper ... public is welcome to participate in the conference ... Jaffray Annual Healthcare ConferencePresenter:  , Ron Squarer, Chief ... Eastern Time Webcast: , ...
(Date:11/24/2015)... , Nov. 24, 2015  DILON Diagnostics and ... signed an agreement for DILON to distribute GE,s Discovery ... the globe. The signing of this distribution agreement will provide ... Molecular Breast Imaging system and is considered an initial ... better healthcare solutions for clinicians and their patients. ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... Many people know of the common symptoms of low thyroid hormone (also ... many people who find their cholesterol levels and weight are creeping up are more ... they don’t have any of the other symptoms. , Thyroid hormone plays a major ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... is offering lower prices in an early celebration of the early holiday shopping ... price of $29.95 each (normally $33.95 ea). Black Friday promotional pricing is in ...
(Date:11/24/2015)... ... ... New patients who wish to seek treatment for missing teeth can now ... Mississauga, ON practice. Dr. Williams has been providing dental service for over 34 years, ... teeth can lead to a variety of complications if they are not replaced quickly, ...
(Date:11/24/2015)... ... November 24, 2015 , ... In an article ... variables that determine which patients are or are not eligible for bariatric surgery. The ... BMI over 40, are more than 100 pounds overweight, or have a BMI of ...
(Date:11/24/2015)... ... , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the FDA, ... FDA has long asserted that design and manufacture of Laboratory Developed Tests (LDTs) falls ... meet the device regulations. , Come up short in an inspection and the FDA ...
Breaking Medicine News(10 mins):